Keryx Biopharmaceuticals (KERX) Gets Another 'Going to $15' Call
Tweet Send to a Friend
Another analyst is on the Keryx Biopharmaceuticals (NASDAQ: KERX) 'going to $15' bandwagon following positive Phase 3 data.
In ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
In ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
